Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Allison

Showing results (61-70 of 226) with videos related to

Pageof 23
Sort By:
International Immunology|May 12, 2004
MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4)William Stohl, Dong Xu, Kyoung Soo Kim, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 19, 2003
Prostate cancer: advances in immunotherapyArthur A Hurwitz, Paul Yanover, Mary Markowitz, et al.
Genomics|October 4, 2006
A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptorsXingxing Zang, P'ng Loke, Jayon Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 26, 2024
Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacyStephen Mok, Didem Ağaç Çobanoğlu, Huey Liu, et al.
The Journal of Experimental Medicine|June 12, 2013
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4Rikke B Holmgaard, Dmitriy Zamarin, David H Munn, et al.
Annual Review of Medicine|November 6, 2013
Immune modulation in cancer with antibodiesDavid B Page, Michael A Postow, Margaret K Callahan, et al.
Current Protocols in Immunology|April 25, 2008
The TRAMP mouse as a model for prostate cancerArthur A Hurwitz, Barbara A Foster, James P Allison, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 28, 2015
Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readinessVirginia A Pedicord, Justin R Cross, Welby Montalvo-Ortiz, et al.
The Journal of Experimental Medicine|July 8, 2009
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodiesKarl S Peggs, Sergio A Quezada, Cynthia A Chambers, et al.
Blood|May 31, 2002
The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptorCynthia A Chambers, Joonsoo Kang, Yongjian Wu, et al.
Pageof 23

Showing results (61-70 of 226) with videos related to

Sort By:
Pageof 23
International Immunology|May 12, 2004
MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4)William Stohl, Dong Xu, Kyoung Soo Kim, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 19, 2003
Prostate cancer: advances in immunotherapyArthur A Hurwitz, Paul Yanover, Mary Markowitz, et al.
Genomics|October 4, 2006
A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptorsXingxing Zang, P'ng Loke, Jayon Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 26, 2024
Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacyStephen Mok, Didem Ağaç Çobanoğlu, Huey Liu, et al.
The Journal of Experimental Medicine|June 12, 2013
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4Rikke B Holmgaard, Dmitriy Zamarin, David H Munn, et al.
Annual Review of Medicine|November 6, 2013
Immune modulation in cancer with antibodiesDavid B Page, Michael A Postow, Margaret K Callahan, et al.
Current Protocols in Immunology|April 25, 2008
The TRAMP mouse as a model for prostate cancerArthur A Hurwitz, Barbara A Foster, James P Allison, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 28, 2015
Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readinessVirginia A Pedicord, Justin R Cross, Welby Montalvo-Ortiz, et al.
The Journal of Experimental Medicine|July 8, 2009
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodiesKarl S Peggs, Sergio A Quezada, Cynthia A Chambers, et al.
Blood|May 31, 2002
The lymphoproliferative defect in CTLA-4-deficient mice is ameliorated by an inhibitory NK cell receptorCynthia A Chambers, Joonsoo Kang, Yongjian Wu, et al.
Pageof 23